Nycomed

NycomedNycomed is a privately owned global pharmaceutical company with a differentiated portfolio focused on branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. An extensive range of OTC products completes the portfolio.

Its R&D is structured around partnerships and in-licensing is a cornerstone of the company's growth strategy.

Nycomed employs 12,000 associates worldwide, and its products are available in more than 100 countries. It has strong platforms in Europe and in fast-growing markets such as Russia/CIS and Latin America. While the US and Japan are commercialised through best-in-class partners, Nycomed plans to further strengthen its own position in key Asian markets.

Headquartered in Zurich, Switzerland, the company generated total sales of €3.2 billion in 2009 and an adjusted EBITDA of €1.1 billion.

www.nycomed.com

Nycomed RSS Channel

Display # 
Title Published Date
Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth 18 January 2012
Nycomed reports double-digit growth across emerging markets in second quarter 2011 17 August 2011
Nycomed to market Roche's osteoporosis treatment Bonviva in key Asia-Pacific markets 16 June 2011
Nycomed continues to outperform in emerging markets in first quarter 2011 26 May 2011
Nycomed acquires distribution rights to product portfolio in Turkey 14 April 2011
REACT study to evaluate impact of Daxas® (roflumilast) in patients receiving standard COPD treatment 31 March 2011
Nycomed well positioned in emerging markets 02 March 2011
Nycomed's novel COPD therapy roflumilast receives FDA approval 01 March 2011
Nycomed to acquire Colombian company Farmacol 06 February 2011
Daxas® (Roflumilast) included as a new treatment option in latest international COPD guidelines 06 January 2011
Nycomed is keeping the pace in third quarter 2010 10 November 2010
Nycomed to accelerate expansion in China 01 November 2010
Global market launch of Daxas® (Roflumilast) kicks off in Germany 01 September 2010
Nycomed's Daxas® (roflumilast) receives marketing authorisation in the European Union 07 July 2010
Nycomed and Merck & Co., Inc., announce commercialization agreements for Daxas® 03 May 2010
Nycomed and Baxter receive FDA approval for TachoSil® 08 April 2010
Nycomed on track in 2009 with strong growth in Key Products 02 March 2010
Nycomed reports continued satisfactory performance in the third quarter 2009 13 November 2009
Nycomed reports sustained momentum in second quarter 2009 20 August 2009
Nycomed and Forest Laboratories to collaborate on US commercialisation of Daxas® in COPD 11 August 2009

Most Popular Now

Boehringer Ingelheim increases acce…

Boehringer Ingelheim is announcing an expansion of its Intellectual Property (IP) enforcement policy. The IP enforcement policy had already been amended in 2007 by an eas...

Read more

AstraZeneca licenses Zurampic to Gr…

AstraZeneca today announced that it has entered into a licensing agreement with Grünenthal GmbH for the exclusive rights to Zurampic (lesinurad) in Europe and Latin Ameri...

Read more

Pfizer presents promising data from…

Pfizer Inc. (NYSE:PFE) today announced encouraging new data from a Phase 1/2 study of lorlatinib, the proposed generic name for PF-06463922, Pfizer's investigational, nex...

Read more

Bayer Science & Education Found…

Applications for the Bayer Science & Education Foundation's international scholarship programs are now being accepted for this year's round. In the academic sector, ambit...

Read more

Merck Accelerator expands its reach…

Merck, a leading science and technology company, has started this week the application period for the next round of its Accelerator programs in Darmstadt, Germany, and Na...

Read more

Merck announces survey results expl…

Merck, a leading science and technology company, today announced survey results of 250 global biopharmaceutical executives on how their companies will manage new risks as...

Read more

Call for Abstracts: DIA EuroMeeting…

29 - 31 March 2017, Glasgow, UK. The DIA EuroMeeting 2017 provides a platform for experts from all relevant disciplines within the entire healthcare development and acce...

Read more

AstraZeneca enters commercialisatio…

AstraZeneca today announced it has entered into a commercialisation agreement with Aspen Global Incorporated (AGI), part of the Aspen Group, for rights to its global anae...

Read more

Promising treatment prospects for i…

In Switzerland alone, more than 5,700 women are diagnosed with breast cancer each year, and almost 1,400 of those affected die of the disease. In many very invasive forms...

Read more

Boehringer Ingelheim and Harvard sc…

Boehringer Ingelheim today announced it has established a research collaboration with the Harvard Stem Cell Institute's - Harvard Fibrosis Network to discover new ways of...

Read more

FDA targets unlawful internet sales…

The U.S. Food and Drug Administration, in partnership with international regulatory and law enforcement agencies, announced that it took action this week against 4,402 we...

Read more

New class of protein could treat ca…

A protein designed by researchers at Georgia State University can effectively target a cell surface receptor linked to a number of diseases, showing potential as a therap...

Read more

Digest World Pharma Newsletter

Subscribe to our weekly Digest World Pharma Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]